SK Biopharmaceuticals

SK Biopharmaceuticals is a global biopharmaceutical company conducting drug research, development, and commercialization worldwide.

: Public
: 1993
: Seongnam-si, Gyeonggi-do, KR

Library

skbp.comCrawled Oct 27, 2026

Product

6 pages

Capacity.do/kor/rnd/capacity.do
Centralnerve.do/kor/rnd/centralnerve.do
Pipeline.do/kor/pipeline/pipeline.do
Product.do/kor/product.do

Press

2 pages

List.do/kor/news/list.do
List.do/eng/news/list.do

Careers & Hiring

4 pages

Careers.do/kor/recruit/careers.do
Careers.do/eng/recruit/careers.do
Talent.do/kor/sustainability/talent.do
Talent.do/eng/sustainability/talent.do

Team

4 pages

Committees.do/kor/invest/committees.do
Committees.do/eng/invest/committees.do
Directors.do/kor/invest/directors.do
Directors.do/eng/invest/directors.do

About

6 pages

Esg.do/kor/sustainability/esg.do
History.do/kor/company/history.do
Network.do/kor/company/network.do
Overview.do/kor/company/overview.do

Contact

4 pages

Ethics Inquery.do/kor/ethics/ethics_inquery.do
Ethics Inquery.do/eng/ethics/ethics_inquery.do
Inquiry.do/kor/company/inquiry.do
Inquiry.do/eng/company/inquiry.do

Homepage

1 page

skbp.com/

Privacy

2 pages

Privacyview.do/kor/privacy/privacyView.do
Privacyview.do/eng/privacy/privacyView.do

Terms & Conditions

1 page

Prevention of corruption/kor/ethics/preventionofcorruption.do

Coverage

6 items

SK Biopharmaceuticals' Second Drug Hits FDA Safety Hurdleen.sedaily.com/finance/2026/09/14/sk-biopharmaceuticals-second-drug-hits-fda-safety-hurdle
The FDA imposes a partial clinical hold on SK Biopharmaceuticals’ epilepsy drug candidate **opacalim**, halting new patient enrollment in a Phase 2/3 trial. This marks the second SK Biopharmaceuticals drug to face regulatory delays after safety concerns. The hold applies specifically to one trial while other studies continue under review.
Sep 2026Seoul Economic DailyNews article
SK Biopharmaceuticals CEO Buys 180 Million Won of Company Stocken.sedaily.com/finance/2026/08/31/sk-biopharmaceuticals-ceo-buys-180-million-won-of-company
SK Biopharmaceuticals CEO **Lee Dong-hoon** purchased **2,000 shares worth 180 million won** following the company’s recent licensing of **Opakalim**, an epilepsy drug candidate. The transaction occurred one day after the drug’s licensing announcement. The move signals confidence in the company’s pipeline amid regulatory progress for its therapeutic candidate.
Aug 2026Seoul Economic DailyNews article
SK Biopharmaceuticals Bets on AI for Next-Generation Drug Developmenten.sedaily.com/culture/2026/06/23/sk-biopharmaceuticals-bets-on-ai-for-next-generation-drug
SK Biopharmaceuticals partners with Insilico Medicine to use AI in discovering new drug targets and small-molecule candidates. The collaboration aims to accelerate next-generation drug development through advanced computational methods. This marks a significant step in integrating AI into pharmaceutical research.
Jun 2026Seoul Economic DailyNews article
SK Biopharmaceuticals will unveil the results of its research on radioactive drugs (RPT), which will.. - MKmk.co.kr/en/it/12009449
SK Biopharmaceuticals unveils its research findings on radioactive pharmaceutical therapies (RPT) at an international event, positioning the technology as a next-generation growth driver. The company highlights its first global disclosure of clinical or preclinical data in this emerging field. Developments focus on potential applications in oncology and other therapeutic areas.
Apr 2026매일경제News article